RESULTS
Among a total of 66 subjects who gave informed consent, 20 subjects were randomly assigned to sequence A (n = 10) or sequence B (n = 10). All subjects received the study drugs in period I and period II (Figure 2). Baseline demographics were generally similar across all treatment groups (Table 1). There were no exclusions from the analysis, and all 20 subjects were included in the PK analysis set and safety analysis set. Twenty subjects received carotegrast methyl alone, and carotegrast methyl and rifampicin in combination. Plasma drug concentration profiles of carotegrast methyl, carotegrast, M-I, M-II and carotegrast-gluc after single oral administration of carotegrast methyl in the presence and absence of rifampicin under fasting conditions are shown in Figure 3. The PK parameters are shown in Table 2. Drug-drug interactions between carotegrast methyl and its metabolites, and rifampicin are shown in Table 3.